Jules: Can you tell me what trials are taking place at the moment?
Sally Fox, Neurology Research Nurse: We’ve got a number of drugs trials at the moment at Leeds General Infirmary. So we’ve got some drugs looking at monoclonal antibodies and their function is to control your immune system and hopefully to, generally to reduce the number of circulating white blood cells that can cross the barrier into your brain and start attacking your brain cells. So we’ve got one at the moment into a drug called Ocrelizumab, we’re looking at starting another one later in the year. We’ve got a number of trials looking at, there’s an exciting new drug called Siponimod in secondary progressive MS. We’ve had some promising results with that, so we’re currently following some patients through.
And we’re also looking at some neuro-protective drugs. So we’re looking at drugs used for heart failure, we’ve got a drug called Melide [ph], an antidepressant called Fluoxetine, and a drug called Wilazel [ph]. So we’re looking at potential neuroprotective roles. So, something different that you would normally use those drugs for. And again, in the autumn we’re looking at starting a trial into a statin, which again, we’re hoping actually might be able to have some neuroprotective effects. In addition to that, like I said before, we’re looking at the experience of MS, so looking at job retention, decision making processes, the sort of looking more holistically at MS and how people cope with that.
Jules: And is there any particular one that you are really excited about or you think…
Sally Fox: I think they’re all exciting in their own way. I think the Ocrelizumab is an exciting one because we’ve had some – we’re not looking at that in primary progressive MS, however, it has had some exciting results in other trials in primary progressive MS. We’re looking at that in relapsing remitting MS and again, that looks promising. Another one that I’m quite excited about actually is the Siponimod trial, because that’s for secondary progressive MS and we’ve had some good results with that and we’ve had some, obviously subjectively, a lot of patients have been pleased in Leeds with the effects of the drug. And I’ve found that particularly exciting, because for secondary progressive MS patients, there isn’t an awful lot out there at the moment, so to know that we’re working on something that’s looking promising, I find that very exciting.
Join the Shift.ms community: https://shift.ms/
Watch more videos here: